Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 15, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Statistical methods and tool for cut point analysis in immunogenicity assays.

Lanju Zhang1, Jianchun Jason Zhang, Robert J Kubiak

  • 1Abbvie Inc, One North Waukegan Road, North Chicago, IL 60064, United States. lanju.zhang@abbvie.com

Journal of Immunological Methods
|January 12, 2013
PubMed
Summary

Determining cut points in immunogenicity assay validation is crucial for biopharmaceutical product safety and efficacy. This study presents a statistically sound yet simple procedure for cut point determination, along with a user-friendly software tool.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Joint association of triglyceride-glucose index and atherogenic lipid markers with incident stroke risk.

Scientific reports·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS (<u>PART 3A</u> - Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).

Bioanalysis·2026
Same author

Cut Point in Immunogenicity Testing: A Flawed Concept We Can Live Without.

The AAPS journal·2025
Same author

Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.

Brain communications·2025
Same author

2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation <u>(PART 3A</u> - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).

Bioanalysis·2025
Same author

A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.

Clinical and translational science·2024

Area of Science:

  • Biopharmaceutical science
  • Immunology
  • Biostatistics

Background:

  • Biopharmaceutical products can elicit immune responses, affecting safety and efficacy.
  • Regulatory agencies require immunogenicity evaluation using validated assays.
  • Assay validation necessitates a defined cut point for reliable results.

Purpose of the Study:

  • To address the need for practical and statistically justified methods for cut point determination in immunogenicity assay validation.
  • To provide a balanced approach between statistical rigor and ease of implementation for scientists.
  • To offer a guide for cut point analysis in biopharmaceutical development.

Main Methods:

  • Discussion of statistical considerations including data normalization, outlier detection, and cut point calculation.

More Related Videos

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Related Experiment Videos

Last Updated: May 15, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

  • Development of a simplified statistical procedure for cut point determination.
  • Creation of an automated software tool using R language to implement the procedure.

    • Main Results:

    • A practical statistical procedure for cut point determination in immunogenicity assays is proposed.
    • The procedure balances statistical rigor with implementation simplicity.
    • An R-based software tool is developed to automate the proposed cut point determination process.

    Conclusions:

    • The proposed approach provides scientists with a practical guide for cut point determination in immunogenicity assay validation.
    • The automated tool facilitates the implementation of a statistically sound and simple procedure.
    • This work aims to enhance the reliability and efficiency of immunogenicity testing in biopharmaceutical development.